Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385501 | 0.86 | ENPP2 (0.41) | KMT2ALMNAENPP2PPARGPPARA | |
| SCHEMBL29643703 | 0.86 | ENPP2 (0.41) | KMT2ALMNAENPP2PPARGPPARA | |
| SCHEMBL2405812 | 0.84 | ENPP2 (0.37) | KMT2ALMNAENPP2ORAI1ORAI2 | |
| SCHEMBL1138230 | 0.77 | NPC1 (0.33) | TSHRHSD17B10ALDH1A1CYP3A4TDP1 | |
| SCHEMBL2407958 | 0.76 | ORAI1 (0.44) | ORAI1ORAI2ORAI3TRPV6ALDH1A1 | |
| SCHEMBL246398 | 0.74 | ENPP2 (0.42) | KMT2ALMNAENPP2TSHRHSD17B10 | |
| SCHEMBL31208432 | 0.74 | ENPP2 (0.42) | KMT2ALMNAENPP2TSHRHSD17B10 | |
| SCHEMBL1138651 | 0.73 | GAA (0.42) | KMT2AENPP2ORAI1ORAI2ORAI3 | |
| SCHEMBL530450 | 0.72 | — | — | |
| SCHEMBL29443091 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| WO-2010018837-A2 | PROTEIN CROSS-LINKING INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018836-A2 | POLYGLUTAMINE AGGREGATION INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| EP-1732527-A2 | USE AND ADMINISTRATION OF BACTERIAL EFFLUX PUMP INHIBITORS | MPEX PHARMACEUTICALS, INC. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1339725-B1 | DNA METHYL TRANSFERASE INHIBITORS | PENN STATE RES FOUND (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | BENKOVIC STEPHEN J | 2005-10-13 | — | — | US | disclosed |
| WO-2005089738-A2 | USE AND ADMINISTRATION OF BACTERIAL EFFLUX PUMP INHIBITORS | MPEX PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | KMT2A 1067/4885LMNA 3426/4885ENPP2 3251/4885 |
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | DNMT1, TPMT, GNMT | KMT2A 120/4885LMNA 3997/4885ENPP2 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.